News
Naming a New Drug During a Pandemic
View Story
Updates: Lilly's Global COVID-19 Response
View Story
Lilly's COVID-19 Science Leads to a Second FDA Emergency Use Authorization
View Story
Time to Tear Down the Rebate Wall
View Story
When the World Called for Help with COVID-19, We Were Ready
View Story
Dave Ricks Shares About Lilly's FDA Emergency Use Authorization for a Neutralizing Antibody
View Story
December 2, 2020
Tags | Product
INDIANAPOLIS , Dec. 2, 2020 /PRNewswire/ -- The U.S. government has purchased 650,000 additional doses of Eli Lilly and Company's (NYSE: LLY) neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. The purchase agreement is for $812.5 million and the doses will be delivered through January 31, 2021
November 24, 2020
Tags | Financial
INDIANAPOLIS , Nov. 24, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1, 2020 . Michael Mason , Lilly senior vice president and president of Lilly Diabetes and Connected Care, will participate in a
November 20, 2020
Tags | Product
- Bamlanivimab emerged from collaboration between Lilly and Vancouver-based AbCellera INDIANAPOLIS , Nov. 20, 2020 /PRNewswire/ -- Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use
November 20, 2020
Tags | Corporate
Research collaboration using ARCUS genome editing technology will initially include three gene targets, with right to select three additional gene targets; lead program focused on Duchenne Muscular Dystrophy Precision will receive $100 million cash upfront and an equity investment by Lilly of $35